In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic, Abbott Swap to Stay In Drug Stent Race

Executive Summary

Medtronic and Abbott Laboratories, both lagging in the race to develop drug-eluting stents, are teaming up to bolster their respective programs in that field. Medtronic lacks a viable anti-restenosis drug and a polymer coating, while Abbott doesn't have a delivery system. Yet, Medtronic has an over-the-wire delivery system and Abbott has a promising anti-proliferative agent in clinical trials. Together, the companies believe they can become viable players in what is sure to be a lucrative, albeit fiercely competitive market.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts